worldwide offices | stay connected | contact | help | sitemap

 
 

 

 

 

Novartis Research and Development (R&D)

Novartis Research and Development (R&D)

Publications

2007

  • Shui, Guanghou; Bendt, Anne K.; Pethe, Kevin; Dick, Thomas; Wenk, Markus R. Sensitive profiling of chemically diverse bioactive lipids. Journal of Lipid Research (2007), 48(9), 1976-1984.
  • Fink, Joshua; Gu, Feng; Ling, Ling; Tolfvenstam, Thomas; Olfat, Farzad; Chin, Keh Chuang; Aw, Pauline; George, Joshy; Kuznetsov, Vladimir A.; Schreiber, Mark; Vasudevan, Subhash G.; Hibberd, Martin L. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Neglected Tropical Diseases (2007), 1(2), e86.
  • Umareddy, Indira; Pluquet, Olivier; Wang, Qing Yin; Vasudevan, Subhash G.; Chevet, Eric; Gu, Feng. Dengue virus serotype infection specifies the activation of the unfolded protein response. Virology Journal (2007), 4 No pp. given.
  • Wu, Peter S. C.; Ozawa, Kiyoshi; Lim, Siew P.; Vasudevan, Subhash G.; Dixon, Nicholas E.; Otting, Gottfried. Cell-free transcription/translation from PCR-amplified DNA for high-throughput NMR studies. Angewandte Chemie, International Edition (2007), 46(18), 3356-3358. CODEN: ACIEF5 ISSN:1433-7851.
  • Ng, Chuan Young; Gu, Feng; Phong, Wai Yee; Chen, Yen-Liang; Lim, Siew Pheng; Davidson, Andrew; Vasudevan, Subhash G. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Research (2007), 76(3), 222-231.
  • Löhr, Kristina; Knox, John E.; Phong, Wai Yee; Ma, Ngai Ling; Yin, Zheng; Sampath, Aruna; Patel, Sejal J; Wang, Wei-Ling; Chan, Wai-Ling, Rao, KR; Wang, Gang; Vasudevan, Subhash G; Keller, Thomas H.; Lim, Siew Pheng. Yellow fever virus NS3 protease: peptide-inhibition studies. J Gen Virol. (2007), 88(8):2223-7.
  • Pichota, Arkadius; Duraiswamy, Jeyaraj; Yin, Zheng; Keller, Thomas Hugo; Schreiber, Mark. Preparation of N-formyl hydroxylamine compounds as peptide deformylase inhibitors. PCT Int. Appl. (2007), 124pp.
  • Jiricek, Jan; Patel, Sejal; Keller, Thomas Hugo; Barry, Clifton E., III; Dowd, Cynthia S. Preparation of nitroimidazole compounds useful in the treatment of infections caused by Mycobacterium tuberculosis, Trypanosoma cruzi or Leishmania donovani. PCT Int. Appl. (2007), 78pp.
  • Pryor, Melinda J.; Rawlison Stephen M.; Butcher, Rebecca E.; Barton, Chenoa L.; Waterhouse, Tracey A.; Vasudevan, Subhash G.; Bardin, Philip G.; Wright, Peter J.; Jans, David A.; Davidson, Andrew D. Nuclear Localization of Dengue Virus Nonstructural Protein 5 Through Its Importin alpha/beta-Recognized Nuclear Localization Sequences is Integral to Viral Infection. Traffic. (2007), 8(7):795-807.
  • Schreiber, Mark J.; Ong, Swee Hoe; Holland, Richard C.; Hibberd, Martin L.; Vasudevan, Subhash G.; Mitchell WP; Holmes, Edward C. DengueInfo: A web portal to dengue information resources. Infect Genet Evol. (2007), 7(4):540-541.
  • Schul, Wouter; Liu, Wei; Xu, Haoying; Flamand, Marie; Vasudevan, Subhash G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. (2007), 195(5):665-674.
  • Yap, Thai Leong; Xu, Ting; Chen, Yen-Liang; Malet, Helene; Egloff, Marie-Pierre; Canard, Bruno; Vasudevan, Subhash G.; Lescar, Julien. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. Journal of Virology (2007), 81(9):4753-4765.
  • Yap, Thai Leong; Chen, Yen Liang; Xu, Ting; Wen, Daying; Vasudevan, Subhash G.; Lescar, Julien. A multi-step strategy to obtain crystals of the dengue virus RNA-dependent RNA polymerase that diffract to high resolution. Acta Crystallographica, Section F: Structural Biology and Crystallization Communications (2007), F63(2): 78-83.

 


Back to top

Neglected diseases

Neglected diseases

We aim to discover new treatments and prevention methods for major tropical diseases. Learn more about the main tropical diseases:

Access to Medicines

Access to Medicines

In developing countries, access to medicines is limited - and we want to be a leader and partner in finding and implementing solutions to help close the access gap.

Contact